Page 189 - Read Online

Nakamura et al. Hepatoma Res 2019;5:16 Hepatoma Research
DOI: 10.20517/2394-5079.2019.06

Original Article Open Access

Hepatocellular carcinoma recurrence in HCV
patients treated with direct-acting antivirals after
curative treatment

Shinichiro Nakamura 1,14 , Kazuhiro Nouso , Hiroyuki Okada , Hideki Onishi , Shin-ichi Fujioka , Yasuyuki
1,6
1
1
2
Araki , Shouta Iwadou , Takashi Kumada , Hidenori Toyoda , Kenta Motomura , Kazuya Kariyama ,
4
3
4
3
6
5
Haruhiko Kobashi , Toshihiko Kaneyoshi , Masaharu Ando , Akio Moriya , Hideaki Taniguchi , Youichi
7
10
9
8
9
Morimoto , Hiroaki Hagihara , Masatoshi Tanaka 13
11
12
1 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
2 Okayama Saiseikai General Hospital, Okayama 700-8558, Japan.
3 Hiroshima City Hiroshima Citizens Hospital, Hiroshima 731-0293, Japan.
4 Ogaki Municipal Hospital, Gifu 503-8502, Japan.
5 Iizuka Hospital, Fukuoka 820-8505, Japan.
6 Okayama City Hospital, Okayama 700-8557, Japan.
7 Okayama Red Cross General Hospital, Okayama 700-8607, Japan.
8 Fukuyama Medical Center, Hiroshima 720-8520, Japan.
9 Mitoyo General Hospital, Kagawa 769-1695, Japan.
10 Tottori Municipal Hospital, Tottori 680-8501, Japan.
11 Kurashiki Central Hospital, Okayama 710-8602, Japan.
12 Sumitomo Besshi Hospital, Ehime 792-8543, Japan.
13 Yokokura Hospital, Fukuoka 839-0215, Japan.
14 Japanese Red Cross Society Himeji Hospital, Hyogo 670-8540, Japan.
Correspondence to: Dr. Kazuhiro Nouso, Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. E-mail: nouso@cc.okayama-u.ac.jp
How to cite this article: Nakamura S, Nouso K, Okada H, Onishi H, Fujioka S, Araki Y, Iwadou S, Kumada T, Toyoda H, Motomura K,
Kariyama K, Kobashi H, Kaneyoshi T, Ando M, Moriya A, Taniguchi H, Morimoto Y, Hagihara H, Tanaka M. Hepatocellular carcinoma
recurrence in HCV patients treated with direct-acting antivirals after curative treatment. Hepatoma Res 2019;5:16.
http://dx.doi.org/10.20517/2394-5079.2019.06
Received: 21 Jan 2019 First Decision: 13 Mar 2019 Revised: 15 Mar 2019 Accepted: 17 Apr 2019 Published: 14 May 2019
Science Editor: Guang-Wen Cao Copy Editor: Cai-Hong Wang Production Editor: Huan-liang Wu

Abstract
Aim: The increased risk of hepatocellular carcinoma (HCC) recurrence in hepatitis C virus (HCV)-infected patients
treated with direct-acting antivirals (DAAs) after curative treatment for HCC is controversial. The purpose of this study
was to examine the risk of HCC recurrence after DAA therapy.

Methods: We conducted a retrospective cohort study of 312 consecutive patients with HCV-related HCC who received
DAA therapy in participating institutions between September 2014 and July 2016. All patients received curative

© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.hrjournal.net